ReIMAGINE: a prostate cancer research consortium with added value through its patient and public involvement and engagement.

ReIMAGINE aims to improve the current prostate specific antigen (PSA)/biopsy risk stratification for prostate cancer (PCa) and develop a new image-based method (with biomarkers) for diagnosing high/low risk PCa in men.